by John A. Jenkins | Sep 9, 2026 | FOIA, Non-Profits, Politics
FOIAengine: Hundreds of Requests Targeted Biden Connections at Center for American Progress Months before Donald Trump threatened the Center for American Progress, the influential progressive policy organization, with a $5 billion defamation lawsuit,...
by John A. Jenkins | Sep 3, 2026 | FDA, FOIA
FOIAengine: Newly Remade Advisory Committee Green Lights Six Compounds, Despite the Applications Being Pulled Bobby Harshbarger is a Tennessee state senator and pharmacist of noteworthy lineage, with an interesting backstory. Both of his parents are...
by Randy Miller | Aug 20, 2026 | FDA, FOIA, News Media, Politics
FOIAengine: Twenty-One Requests from News Media, Non-Profits and Companies The nationwide outbreak of cyclospora infections this summer prompted a steady stream of national and local news articles, along with 21 Freedom of Information Act requests to the Food and Drug...
by John A. Jenkins | Aug 12, 2026 | FOIA, SEC
As the artificial-intelligence arms race heats up, Meta and Google have turned to Wall Street for help paying the multi-billion-dollar tab. Amid data-center financing terms that even Google’s auditor calls questionable, a Washington securities lawyer whose clients...
by John A. Jenkins | Aug 5, 2026 | FDA, FOIA, Hedge Funds, Pharmaceuticals, Stock Market
FOIAengine: Requests from Point72, Sofinnova, Holocene, Triple Gate and Others A review of the latest Freedom of Information Act requests targeting three life-sciences companies – Novo Nordisk (NYSE: NVO); Charles River Laboratories (NYSE: CRL); and iRhythm...
by John A. Jenkins | Jul 30, 2026 | FDA, FOIA, News Media, Pharmaceuticals, Politics
FOIAengine: Multiple News Outlets Sought Details on “Compassionate Use” Within days of a Stat News report describing a highly unusual government decision to grant a 79-year-old patient early access to Eli Lilly’s experimental obesity drug retatrutide, some of the...
